Stock · BDX · Healthcare
United States · Large Cap · listed since 1987 · Revenue 12 mo. $20.8B
Price as of 11/06/2026
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Original text from the data provider
Summary
55.7 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €2.4B (2025), it supports €26.6B. The remaining €25B of the market value assume it grows 9.3% a year for 10 years and not at all afterwards.
Required FCF growth per year
9.3%
no growth afterwards
Price to operating cash flow 17.5×, within its usual range.
Middle half of 20 quarters: 12.7× to 19.8×, median 15.0×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Net debt, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 6.61% | 11.52% | Rank 23 |
| Return on capital (Greenblatt) | 32.47% | 32.55% | Rank 50 |
| EBIT margin | 11.80% | 18.31% | Rank 29 |
| FCF margin | 12.23% | 14.12% | Rank 39 |
| Gross margin | 45.44% | 60.99% | Rank 31 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 8.23% | 8.04% | Rank 50 |
| Earnings growth, 3 years per year | −1.90% | 5.44% | Rank 31 |
| Earnings growth, 5 years per year | 13.56% | 7.00% | Rank 64 |
| Sustainable growth (ROE × retained earnings) | 3.48% | 3.66% | Rank 45 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.76% | 2.90% | Rank 45 |
| FCF yield | 4.64% | 3.63% | Rank 66 |
| EV/saleslower is better | 3.47 | 4.03 | Rank 54 |
| EV/EBITlower is better | 29.41 | 21.73 | Rank 29 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 42.32% | 8.66% | Rank 85 |
| Share price, 6 months | 42.28% | 24.27% | Rank 80 |
| Share price, 3 months | 24.93% | 15.42% | Rank 82 |
| Distance from 52-week high | −0.78% | −7.35% | Rank 87 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −1.66% | 0.30% | Rank 69 |
| Change in share countlower is better | −1.34% | 0.00% | Rank 71 |
| Dividend streak in years | 42 | 10 | Rank 98 |
| Price reaction to results, market-adjusted | 4.00% | 0.05% | Rank 80 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 45.89% | 48.40% | Rank 42 |
| Net debt/EBITDAlower is better | 3.70 | 1.11 | Rank 8 |
| Debt to equitylower is better | 0.76 | 0.48 | Rank 32 |
| Volatility, 1 yearlower is better | 26.07% | 31.42% | Rank 83 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 12.5 | 11.5% | 1.8 | 218M | 10.0 |
| 2017 | 12.1 | 12.6% | 1.8 | 224M | 4.7 |
| 2018 | 16.0 | 9.4% | 2.0 | 265M | 20.4 |
| 2019 | 17.3 | 10.2% | 2.4 | 275M | 18.9 |
| 2020 | 16.1 | 5.7% | 2.7 | 282M | 15.1 |
| 2021 | 19.1 | 11.8% | 3.4 | 292M | 16.0 |
| 2022 | 18.9 | 12.1% | 1.7 | 287M | 15.8 |
| 2023 | 19.4 | 10.9% | 2.1 | 288M | 15.3 |
| 2024 | 20.2 | 11.9% | 3.1 | 291M | 19.7 |
| 2025 | 21.8 | 11.8% | 2.7 | 287M | 18.3 |
2 of 7 StockScorer Score rules met · How the score is built
Becton Dickinson and Company mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Becton Dickinson and Company is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
2 of 7 rules met
3 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Becton Dickinson and Company.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 36.3 | 30.0 |
| P/B ratio | 2.4 | 4.8 |
| Return on equity (ROE) | 6.6% | 11.5% |
| Equity ratio | 45.9% | 48.4% |
| Debt-to-equity (D/E) | 0.76 | 0.48 |
| Dividend yield | 1.9% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| BDX | Becton Dickinson and Companythis page | |
| MDLN | Medline Inc. Class A Common Stock | locked |
| RMD | ResMed Inc | High7.3 |
| WST | West Pharmaceutical Services Inc | Low3.6 |
| SOLV | Solventum Corp. | locked |
| ISRG | Intuitive Surgical Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.